An observational study in TIPS, Portal Hypertension and Porto-Sinusoidal Vascular Disease, sponsored by Centre Hospitalier Universitaire, Amiens. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-19.
Sponsored by Centre Hospitalier Universitaire, Amiens · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Porto-sinusoidal Vascular Disease (PSVD) is characterized by a portal hypertension (PH) without cirrhosis. This can induce PH complications, like digestive hemorrhage from esophageal or gastric varices, ascites, or even portal thrombosis. Due to the rarity of MVPS, the treatment of complications of portal hypertension is modeled on the methods used in cirrhotic portal hypertension with non-cardio-selective beta blockers, endoscopic ligations or diuretics in first line therapy, as proposed by the Baveno VII recommendations. In complicated or refractory forms of PH in PSVD, the place of TIPS is also discussed, as in the field of cirrhosis. However, the experience of TIPS in PSVD is limited, reported in case reports and small specifically dedicated series. No predictive factors for survival or recurrence and tolerance were well known. A larger study with control group is needed in order to better know the right time and the right indication for the use of TIPS in complicated PH PSVD-related.
The study will be retrospective, multicentric involving tertiary university French centers, expert in the management of TIPS. Patients white TIPS-PSVD will be compared with historical patients with TIPS-cirrhose, matched on age, sexe, indication of TIPS. The study will not comprise new intervention, only observational in a real life condition
150 studies on the registry are indexed under Esophageal and Gastric Varices; 39 are open to participants now.
This study's planned enrollment of 360 is above the median of 130 across 44 observational studies indexed under Esophageal and Gastric Varices.
Browse Esophageal and Gastric Varices studies →Centre Hospitalier Universitaire, Amiens is the lead sponsor of 586 studies on the registry; 185 are open to participants now.
Compared within Esophageal and Gastric Varices, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hypertension, Portal. The counts are of registry records indexed under each term, refreshed daily. How we classify →
The study will be retrospective and observational, collecting data provided in 24 tertiary french University Hospital (CHU).
All patients with PSVD with a PH and treated by TIPS will be included (group TIPS_PSDV) and compared with an historical group of patients with Cirrhosis with a TIPS (group TIPS-cirrhose).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
experimental group
historical control group
overall survival after TIPS placement
Time frame: at 3 months
overall survival after TIPS placement
Time frame: at 6 months
overall survival after TIPS placement
Time frame: at 1 year
overall survival after TIPS placement
Time frame: at 2 years
overall survival after TIPS placement
Time frame: at 3 years
overall survival after TIPS placement
Time frame: at 4 years
overall survival after TIPS placement
Time frame: at 5 years
free portal hypertension hemorrhage recurrence survival
Time frame: at 3 months
free portal hypertension hemorrhage recurrence survival
Time frame: at 6 months
free portal hypertension hemorrhage recurrence survival
Time frame: at 1 year
free portal hypertension hemorrhage recurrence survival
Time frame: at 2 years
free portal hypertension hemorrhage recurrence survival
Time frame: at 3 years
free portal hypertension hemorrhage recurrence survival
Time frame: at 4 years
free portal hypertension hemorrhage recurrence survival
Time frame: at 5 years
free ascite recurrence survival
Time frame: at 3 months
free ascite recurrence survival
Time frame: at 6 months
free ascite recurrence survival
Time frame: at 1 year
free ascite recurrence survival
Time frame: at 2 years
free ascite recurrence survival
Time frame: at 3 years
free ascite recurrence survival
Time frame: at 4 years
free ascite recurrence survival
Time frame: at 5 years
free TIPS dysfunction survival
Time frame: at 3 months
free TIPS dysfunction survival
Time frame: at 6 months
free TIPS dysfunction survival
Time frame: at 1 year
free TIPS dysfunction survival
Time frame: at 2 years
free TIPS dysfunction survival
Time frame: at 3 years
free TIPS dysfunction survival
Time frame: at 4 years
free TIPS dysfunction survival
Time frame: at 5 years
complication of TIPS placement at D0
Time frame: at 3 months
complication of TIPS placement at D0
Time frame: at 6 months
complication of TIPS placement at D0
Time frame: at 1 year
complication of TIPS placement at D0
Time frame: at 2 years
complication of TIPS placement at D0
Time frame: at 3 years
complication of TIPS placement at D0
Time frame: at 4 years
complication of TIPS placement at D0
Time frame: at 5 years
Plan to share: No
No publications or documents are linked to this record.
Started May 2025 (actual). Primary completion is estimated for Dec 2025, 7 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Esophageal and Gastric Varices →
Centre Hospitalier Universitaire, Amiens →